30.91 
0.09(0.29%) 2:43PM EST - Nasdaq Real Time Price
| Prev Close: | 31.00 |
|---|
| Open: | 31.23 |
|---|
| Bid: | 30.93 x 9800 |
|---|
| Ask: | 30.94 x 18500 |
|---|
| 1y Target Est: | 32.64 |
|---|
| Beta: | 0.84 |
|---|
| Next Earnings Date: | 29-Jan-14 |
|---|
| Day's Range: | 30.86 - 31.33 |
|---|
| 52wk Range: | 23.55 - 31.40 |
|---|
| Volume: | 15,691,302 |
|---|
| Avg Vol (3m): | 25,248,300 |
|---|
| Market Cap: | 204.63B |
|---|
| P/E (ttm): | 8.53 |
|---|
| EPS (ttm): | 3.63 |
|---|
| Div & Yield: | 0.96 (3.10%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Wal-Mart Blames Tech Glitch for Temporary Weird Prices and 2 Other Dow Movers to Watchat Wall St. Cheat Sheet(Wed 1:38PM EST)
- SAC Civil Money-Laundering Settlement Approved by Judgeat Bloomberg(Wed 12:41PM EST)
- [video] Regeneron CEO: More opportunities to grow Eyleaat CNBC(Tue, Nov 5)
- Ligand Pharmaceuticals On Pace For Annual Profitat Investor's Business Daily(Tue, Nov 5)
- Big Pharma Can't Capitalize on the Dow's Big Reboundat Motley Fool(Tue, Nov 5)
- FDA Okays Pfizer’s Embeda Extended Release Capsules and 2 Other Hot Stocks to Watchat Wall St. Cheat Sheet(Tue, Nov 5)
- Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health ConcernBusiness Wire(Tue, Nov 5)
- Merck Seen Unlocking $13 Billion With Breakup: Real M&Aat Bloomberg(Tue, Nov 5)
- SAC Agrees to Plead Guilty to End Insider-Trading Caseat Bloomberg(Tue, Nov 5)
- Risk/Reward Remains Positive For Durectat Seeking Alpha(Tue, Nov 5)
- DURECT's CEO Discusses Q3 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, Nov 4)
- InPlay: Pfizer receives FDA approval for a prior approval supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CIIBriefing.com(Mon, Nov 4)
- Pfizer Receives FDA Approval for a Prior Approval Supplement for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CIIBusiness Wire(Mon, Nov 4)
- One Put, One Call Option To Know About for Pfizerat Forbes(Mon, Nov 4)
- Salix Pharmaceuticals Thrives With Promising GI Drugsat Investor's Business Daily(Mon, Nov 4)
Key Statistics
| Forward P/E (1 yr): | 13.51 |
|---|
| P/S (ttm): | 3.65 |
|---|
| Ex-Dividend Date: | 06-Nov-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.18 |
|---|
| Quarterly EPS Est
(Dec-13)
: | 0.53 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 4.87 |
|---|
Business Summary
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care phys...
View More